Skip to main content
. 2010 May 14;138(5):1156–1165. doi: 10.1378/chest.09-2426

Table 3.

—Asthma Exacerbations (Expert Panel Report 3 Definition) by Score Category

Data Set Low Risk (≤ 5) Average Risk (6-8) High Risk (≥ 9)
Exploratory set (n = 465), No. 121 251 93
 Subjects with outcome, No. (%)a 54 (44.6) 183 (72.9) 87 (93.6)
 OR (95% CI)b 0.2 (0.1-0.3)c 8.3 (3.5-19.5)c
 PV, %d 55.4 93.6
 FPR, %e 16.7 4.3
Validation set (n = 150), No. 44 76 30
 Subjects with outcome, No. (%)a 19 (43.2) 58 (76.3) 27 (90.0)
 OR (95% CI)b 0.2 (0.1-0.4)c 5.4 (1.5-19.2)f
 PV, %d 56.8 90
 FPR, %e 18.3 6.5
CAMP 1 y (n = 1,041), No.g 371 530 140
 Subjects with outcome, No. (%)a 92 (24.8) 185 (34.9) 67 (47.9)
 HR (95% CI)b 0.6 (0.5-0.7)f 1.9 (1.4-2.4)c
 PV, %d 75.2 47.9
 FPR, %e 26.7 10.5
CAMP 2 y (n = 1,041), No.h 371 530 140
 Subjects with outcome, No. (%)a 145 (39.1) 262 (49.4) 95 (67.9)
 HR (95% CI)b 0.6 (0.5-0.8)f 1.9 (1.5-2.4)c
 PV, %d 60.9 67.9
 FPR, %e 28.9 8.3

FPR = false-positive rate; HR = hazard ratio; PV = predictive value. See Table 1 legend for expansion of other abbreviation.

a

Percentage of subjects in the same score category.

b

Adjusted for age, sex, and parental education in Costa Rica and for age, sex, race, and treatment group in CAMP.

c

P < .001.

d

PV for no exacerbation in the low-risk group and for exacerbation in the high-risk group.

e

FPR = 1-specificity.

f

P < .05.

g

From start of cohort through 1-y follow-up.

h

From start of cohort through 2-y follow-up.